Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07820435 in advanced solid tumors
NCT06285097Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of PF-07820435 in non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (HNSCC) and 4 more (5 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 2 years and 2 more. Started Feb 2024; status: terminated.
02
Drugs
PF-07820435
03
Conditions
non-small cell lung cancer (NSCLC)melanomasquamous cell carcinoma of the head and neck (HNSCC)renal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06285097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285097.